SCHEMBL6476841

SCHEMBL6476841

COC(=O)CCc1ccc(OCCn2c(=O)oc3cc(C(=O)c4ccccc4)ccc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.56
PPARG P37231 3/20 0.51
ALDH1A1 P00352 6/20 0.50
HPGD P15428 2/20 0.50
ASAH1 Q13510 4/20 0.49
MET P08581 1/20 0.47
RAB9A P51151 2/20 0.46
MAPT P10636 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7028555 0.91 SIGMAR1 (0.57) SIGMAR1PPARGALDH1A1HPGDASAH1
SCHEMBL6483665 0.85 PPARG (0.70) SIGMAR1PPARGALDH1A1HPGDASAH1
SCHEMBL6477277 0.83 PPARG (0.58) SIGMAR1PPARGALDH1A1HPGDASAH1
SCHEMBL6475938 0.82 PPARG (0.74) SIGMAR1PPARGALDH1A1HPGDRAB9A
SCHEMBL6476191 0.81 SIGMAR1 (0.55) SIGMAR1PPARGALDH1A1HPGDASAH1
SCHEMBL6477456 0.81 SIGMAR1 (0.55) SIGMAR1PPARGALDH1A1HPGDASAH1
SCHEMBL6476194 0.81 SIGMAR1 (0.55) SIGMAR1PPARGALDH1A1HPGDASAH1
SCHEMBL6487606 0.81 SIGMAR1 (0.59) SIGMAR1PPARGALDH1A1HPGDASAH1
SCHEMBL6477711 0.79 SIGMAR1 (0.56) SIGMAR1PPARGALDH1A1HPGDASAH1
SCHEMBL7023926 0.79 SIGMAR1 (0.56) SIGMAR1PPARGALDH1A1HPGDASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1252150-B1 HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2003-06-04 EP claimed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US claimed
US-6919362-B2 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2005-07-19 US disclosed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same CYP2F1, CYP11B2, CYP4B1 SIGMAR1 153/4885PPARG 414/4885ALDH1A1 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.